OKYO Pharma Ltd (OKYO): Multiplikator forward rega marang pendapatan

The success of OKYO Pharma Limited (OKYO) is contingent upon the test results of OK-101 for ocular inflammation. The forward EV/Revenue multiple reflects the valuation trend, with the current value standing at . While a single-product strategy introduces risks, it targets a broad consumer segment. The biopharma business in the US and UK relies on a narrow treatment profile for mucosal dryness.
Rincian metrik keuangan lan pasar OKYO Pharma (OKYO)

OKYO Pharma Limited (OKYO) strategic alliances in ophthalmology are driving capitalization dynamics, as clearly reflected in the forward P/S history. This indicator benchmarks the company's market value against expected revenue, allowing investors to assess whether the premium for innovation scalability is justified and to identify the risk of overpaying during peaks of optimism, thereby confirming the fundamental stability of the capital.